Cargando…

Combination of new multifunctional molecules for erythematotelangiectatic rosacea disorder

BACKGROUND: Rosacea, a common chronic skin disorder, is currently managed by patient education, pharmacological drugs, medical devices (laser and light therapies), and use of proper skin cares. Unfortunately, none of these actual treatments used alone or in combination is curative, and so we propose...

Descripción completa

Detalles Bibliográficos
Autores principales: Chajra, Hanane, Nadim, Mahdi, Auriol, Daniel, Schweikert, Kuno, Lefevre, Fabrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598363/
https://www.ncbi.nlm.nih.gov/pubmed/26491365
http://dx.doi.org/10.2147/CCID.S92326
_version_ 1782394071066607616
author Chajra, Hanane
Nadim, Mahdi
Auriol, Daniel
Schweikert, Kuno
Lefevre, Fabrice
author_facet Chajra, Hanane
Nadim, Mahdi
Auriol, Daniel
Schweikert, Kuno
Lefevre, Fabrice
author_sort Chajra, Hanane
collection PubMed
description BACKGROUND: Rosacea, a common chronic skin disorder, is currently managed by patient education, pharmacological drugs, medical devices (laser and light therapies), and use of proper skin cares. Unfortunately, none of these actual treatments used alone or in combination is curative, and so we proposed a dermocosmetic active ingredient to mitigate some aspects of the rosacea and particularly for erythematotelangiectatic rosacea. METHODS: Dermocosmetic active ingredient is composed of three glucosylated derivatives of natural plants hydroxybenzoic acid and hydroxycinnamic acids (rosmarinic acid, gallic acid, and caffeic acid). Anti-inflammatory, anti-angiogenesis, and anti-degranulation studies were done on cellular models (keratinocytes, mast cells, and endothelial cells). Efficiency of the active ingredient in comparison to placebo was assessed clinically on human volunteers having erythematotelangiectatic rosacea. The active and placebo were applied topically twice a day for 28 days. Biometrical analyses were done using a siascope tool. RESULTS: We found that the active ingredient decreases inflammation (inhibition of interleukin-8 and tumor necrosis factor release), decreases degranulation of mast cells (inhibition of histamine release), and controls angiogenesis mechanism (inhibition of the production of vascular endothelial growth factor and neovessel formation) on cellular models. Study on human volunteers confirmed macroscopically the efficiency of this active ingredient, as we observed no neovessel formation and less visible vessels. CONCLUSION: Although rosacea is a skin condition disorder that is difficult to heal, the studies have shown that this active ingredient could be a dermocosmetic support, especially for erythematotelangiectatic rosacea armamentarium. The active ingredient was topically applied on the face for 28 days and improved erythematotelangiectatic rosacea symptoms either by decreasing them (vessels are less visible) or by limiting their development (any neovessels). The active ingredient decreases inflammation (inhibition of interleukin-8 and tumor necrosis factor release), decreases degranulation of mast cells (inhibition of histamine release), and limits the angiogenesis process (inhibition of vascular endothelial growth factor production and neovessel formation).
format Online
Article
Text
id pubmed-4598363
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-45983632015-10-21 Combination of new multifunctional molecules for erythematotelangiectatic rosacea disorder Chajra, Hanane Nadim, Mahdi Auriol, Daniel Schweikert, Kuno Lefevre, Fabrice Clin Cosmet Investig Dermatol Original Research BACKGROUND: Rosacea, a common chronic skin disorder, is currently managed by patient education, pharmacological drugs, medical devices (laser and light therapies), and use of proper skin cares. Unfortunately, none of these actual treatments used alone or in combination is curative, and so we proposed a dermocosmetic active ingredient to mitigate some aspects of the rosacea and particularly for erythematotelangiectatic rosacea. METHODS: Dermocosmetic active ingredient is composed of three glucosylated derivatives of natural plants hydroxybenzoic acid and hydroxycinnamic acids (rosmarinic acid, gallic acid, and caffeic acid). Anti-inflammatory, anti-angiogenesis, and anti-degranulation studies were done on cellular models (keratinocytes, mast cells, and endothelial cells). Efficiency of the active ingredient in comparison to placebo was assessed clinically on human volunteers having erythematotelangiectatic rosacea. The active and placebo were applied topically twice a day for 28 days. Biometrical analyses were done using a siascope tool. RESULTS: We found that the active ingredient decreases inflammation (inhibition of interleukin-8 and tumor necrosis factor release), decreases degranulation of mast cells (inhibition of histamine release), and controls angiogenesis mechanism (inhibition of the production of vascular endothelial growth factor and neovessel formation) on cellular models. Study on human volunteers confirmed macroscopically the efficiency of this active ingredient, as we observed no neovessel formation and less visible vessels. CONCLUSION: Although rosacea is a skin condition disorder that is difficult to heal, the studies have shown that this active ingredient could be a dermocosmetic support, especially for erythematotelangiectatic rosacea armamentarium. The active ingredient was topically applied on the face for 28 days and improved erythematotelangiectatic rosacea symptoms either by decreasing them (vessels are less visible) or by limiting their development (any neovessels). The active ingredient decreases inflammation (inhibition of interleukin-8 and tumor necrosis factor release), decreases degranulation of mast cells (inhibition of histamine release), and limits the angiogenesis process (inhibition of vascular endothelial growth factor production and neovessel formation). Dove Medical Press 2015-10-01 /pmc/articles/PMC4598363/ /pubmed/26491365 http://dx.doi.org/10.2147/CCID.S92326 Text en © 2015 Chajra et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Chajra, Hanane
Nadim, Mahdi
Auriol, Daniel
Schweikert, Kuno
Lefevre, Fabrice
Combination of new multifunctional molecules for erythematotelangiectatic rosacea disorder
title Combination of new multifunctional molecules for erythematotelangiectatic rosacea disorder
title_full Combination of new multifunctional molecules for erythematotelangiectatic rosacea disorder
title_fullStr Combination of new multifunctional molecules for erythematotelangiectatic rosacea disorder
title_full_unstemmed Combination of new multifunctional molecules for erythematotelangiectatic rosacea disorder
title_short Combination of new multifunctional molecules for erythematotelangiectatic rosacea disorder
title_sort combination of new multifunctional molecules for erythematotelangiectatic rosacea disorder
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598363/
https://www.ncbi.nlm.nih.gov/pubmed/26491365
http://dx.doi.org/10.2147/CCID.S92326
work_keys_str_mv AT chajrahanane combinationofnewmultifunctionalmoleculesforerythematotelangiectaticrosaceadisorder
AT nadimmahdi combinationofnewmultifunctionalmoleculesforerythematotelangiectaticrosaceadisorder
AT aurioldaniel combinationofnewmultifunctionalmoleculesforerythematotelangiectaticrosaceadisorder
AT schweikertkuno combinationofnewmultifunctionalmoleculesforerythematotelangiectaticrosaceadisorder
AT lefevrefabrice combinationofnewmultifunctionalmoleculesforerythematotelangiectaticrosaceadisorder